Overview
Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infection leads to a decrease of PH and is associated with an improved outcome. Recently, Bulevirtide was approved for the treatment of patients coinfected with hepatitis B (HBV) and chronic hepatitis delta (HDV) infection, which helps to achieve viral supression in these patients. This study investigates the potential effects of viral supression on PH in patients with chronic HBV/HDV infection and liver cirrhosis.
Eligibility
Inclusion Criteria:
- Chronic HBV/HDV Coinfection
- suspected or diagnosed liver cirrhosis, indication for hepatovenous pressure gradient (HVPG) measurement or liver cirrhosis and HVPG measurement conducted in the past 12 months (conducted prior to antiviral treatment)
- indication for antiviral treatment with Bulevirtide
- age >18years
- Must be willing to participate in the study and provide written informed consent
Exclusion Criteria:
- patient rejects study participation
- no conducted or no indication for HVPG measurement
- age <18years